Table 2.
Details of the 6 Patients with HBV reactivation
| Patients Characteristics | Baseline | At reactivation | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Age (years) | Gender | Cancer type | Anti-tumor therapy | HBV DNA (IU/mL) | Antiviral prophylaxis | Weeks from start of immunotherapy | HBV DNA (IU/mL) | Peak ALT (U/L) | Anti-PD-1/PD-L1 therapy disruption | Antiviral treatment | Time for achieving HBV-DNA undetectable (weeks) | Time for ALT recovery (weeks) |
| 1 | 48 | M | NPC | Camrelizumab | Undetectable | Nil | 3 | 7.81 × 103 | 191.4 | Delayed | Entecavir | 1 | 2 |
| 2 | 47 | M | NPC | Camrelizumab | Undetectable | Nil | 16 | 6.98 × 104 | 203.0 | Delayed | Entecavir | 4 | 4 |
| 3 | 39 | M | Melanoma | Pembrolizumab | Undetectable | Nil | 28 | 2.10 × 103 | 27.6 | No | Nil | 5 | NA |
| 4 | 36 | M | HCC | Nivolumab | Undetectable | Entecavir | 12 | 1.80 × 103 | 298 | Discontinued | Entecavir plus tenofovir | 1 | 3 |
| 5 | 45 | M | HNSCC | Toripalimab | Undetectable | Nil | 35 | 4.04 × 106 | 281.2 | Delay | Entecavir | 3 | 6 |
| 6a | 41 | F | Soft Tissue Sarcoma | Nivolumab | Undetectable | Nil | 20 | 6.00 × 107 | 465.1 | NA | Entecavir | 8 | 4 |
aHBV reactivation in this patient occurred 6 weeks after immunotherapy was discontinued; other HBV reactivation occurred during anti-PD-1/PD-L1 thearpy
Abbreviations: M male, F female, HBV hepatitis B virus, NPC nasopharyngeal carcinoma, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell cancer, ALT alanine aminotransferase, NA not applicable